Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/17/?d=1Neue Studien: Europe PMCdeAssociation between Polycyclic Aromatic Hydrocarbon Metabolites and Psoriasis in US Adults: Evidence from the National Health and Nutrition Examination Survey.https://www.psoriasis-news.de/articles.html/1_articles/association-between-polycyclic-aromatic-hydrocarbon-metabolites-and-psoriasis-in-us-adults-evidence-from-the-national-health-and-nutrition-examination-survey-r137/BackgroundPolycyclic aromatic hydrocarbons (PAHs) are environmental pollutants with widespread human exposure and have been associated with adverse health outcomes. However, their potential relationship with psoriasis remains insufficiently explored.

Objective

The aim of this study is to investigate the association between PAH exposure and psoriasis.

Methods

Data were obtained from the National Health and Nutrition Examination Survey (NHANES) for the periods 2005-2006, 2009-2010, and 2011-2012. Weighted multivariate logistic regression analysis was performed to assess the association between individual PAH metabolites and psoriasis. Bayesian kernel machine regression (BKMR), quantile g-computation (qgcomp), and weighted quantile sum (WQS) regression were used to evaluate the relationship between mixed PAH exposure and psoriasis, as well as to determine the relative contributions of specific PAH metabolites. Stratified and sensitivity analyses were conducted to assess result stability.

Results

A total of 4,912 participants (mean age, 43.52 years; 95% CI, 42.65-44.39 years) were included, of whom 2,514 (51.18%) were female, and 141 (2.87%) were diagnosed with psoriasis. Multivariate logistic regression analysis identified significant positive associations between psoriasis and seven urinary PAH metabolites: 2-hydroxynaphthalene, 3-hydroxyfluorene, 2-hydroxyfluorene, 3-hydroxyphenanthrene, 1-hydroxyphenanthrene, 2-hydroxyphenanthrene, and 1-hydroxypyrene. Analysis of mixed exposure PAH across all three models demonstrated significant positive associations between urinary PAH metabolites and psoriasis, with 2-hydroxyphenanthrene and 2-hydroxynaphthalene identified as primary contributors. Stratified and sensitivity analyses confirmed the robustness of these results, and the observed associations persisted among non-smokers.

Conclusion

Both single and mixed exposure analyses demonstrated a positive association between PAH exposure and psoriasis. These findings suggest that reducing PAH exposure may help mitigate psoriasis risk.

Weiterlesen

]]>137Sat, 12 Jul 2025 18:34:11 +0000Global Guidelines for Psoriatic Arthritis Management: A Comparative Analysis.https://www.psoriasis-news.de/articles.html/1_articles/global-guidelines-for-psoriatic-arthritis-management-a-comparative-analysis-r136/BackgroundPsoriatic arthritis (PsA) is a complex immune-mediated heterogeneous inflammatory disease. Treatment decisions are challenging given the multisystem involvement. To further guide management strategies, we conducted a comparative analysis of the latest global guidelines highlighting the contrast in their approach to treat different PsA domains.

Methods

Major global guidelines for PsA management were reviewed, including American College of Rheumatology 2018 update, European Alliance of Associations for Rheumatology 2023 update, British Society of Rheumatology 2022, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2021, and Pan American League of Associations for Rheumatology 2024.

Results

The guidelines unanimously recommend a treat-to-target strategy with a focus on active PsA. Divergence existed in treatment sequencing regarding the use of biologic and targeted disease-modifying antirheumatic drugs (DMARDs). Variations were also noted in the management of enthesitis and dactylitis. Addressing comorbidities and associated conditions is regarded to be a cornerstone for optimizing disease control and preventing flares.

Conclusion

This review highlights the different management strategies among the global guidelines. Furthermore, we pointed at promising new therapeutic targets that are likely to be incorporated into future recommendations.

Weiterlesen

]]>136Sat, 12 Jul 2025 18:34:11 +0000Validation of patient-reported outcome measures for dactylitis, psoriatic skin and nail disease, and uveitis in patients with psoriatic arthritis in routine care.https://www.psoriasis-news.de/articles.html/1_articles/validation-of-patient-reported-outcome-measures-for-dactylitis-psoriatic-skin-and-nail-disease-and-uveitis-in-patients-with-psoriatic-arthritis-in-routine-care-r135/BackgroundIn routine care, Danish patients with psoriatic arthritis are monitored in the DANBIO registry. In March 2022, patient-reported outcome measures (PROMs) on selected non-musculoskeletal manifestations (NMM) were implemented.

Aim

To validate PROMs for current dactylitis, skin and nail psoriasis, and recent uveitis in patients with psoriatic arthritis.

Methods

Adaptive cross-sectional study. Patients in the rheumatologic clinic answered PROMs with 'yes'/'no'/'do not know' and assessed the extent of skin psoriasis and number of dactylitis-affected digits in DANBIO. PROM entries were compared with the physician's assessments (physical examination, review of patient file), with the physician being the gold standard. With 134 patients included, 20% had incorrectly reported dactylitis; therefore, a dactylitis photo was added to the PROM. Sensitivity, specificity, positive and negative predictive values, accuracy and Cohen's kappa were calculated. Level of agreement for dactylitis count was explored by Bland-Altman plot. From patient 200, the physician was blinded to PROs.

Results

We included 300 patients (51% female, median age=55 years), with a median disease duration of 8 years, where 43% received biologic treatment. According to the physician's assessment, 41 (14%) patients had current dactylitis, 164 (55%) psoriasis, 163 (54%) nail psoriasis and 3 (1%) recent uveitis. For the dactylitis PROM, the sensitivity/specificity/Cohen's kappa was 0.89/0.81/0.57, psoriasis 1.0/0.94/0.95, nail psoriasis 0.76/0.94/0.66 and uveitis 1.00/0.99/0.59. Agreement on psoriasis extent was 90%. Patient-reported dactylitis count was on average 1.0 unit higher than physician-reported but decreased to 0.7 after adding the dactylitis photo. Results were similar irrespective of blinding.

Conclusion

Patients reliably self-report dactylitis, psoriasis, and uveitis and the PROMs are valuable for monitoring NMMs in routine care.

Weiterlesen

]]>135Sat, 12 Jul 2025 18:34:11 +0000A case report of genital psoriasis following transgender vaginoplastyhttps://www.psoriasis-news.de/articles.html/1_articles/a-case-report-of-genital-psoriasis-following-transgender-vaginoplasty-r134/No abstract supplied.

Weiterlesen

]]>134Sat, 12 Jul 2025 18:34:11 +0000Incidence and Clinical Characteristics of Active Tuberculosis in Psoriasis Patients From a High-Burden Setting: An 18-Year Retrospective Study of 86 Patients.https://www.psoriasis-news.de/articles.html/1_articles/incidence-and-clinical-characteristics-of-active-tuberculosis-in-psoriasis-patients-from-a-high-burden-setting-an-18-year-retrospective-study-of-86-patients-r133/Weiterlesen

]]>133Wed, 09 Jul 2025 18:37:42 +0000Psoriatic Arthritis Priority Setting Partnership: patient- and clinician-informed considerations for future UK health service delivery.https://www.psoriasis-news.de/articles.html/1_articles/psoriatic-arthritis-priority-setting-partnership-patient-and-clinician-informed-considerations-for-future-uk-health-service-delivery-r132/ObjectivesLittle is known about the ideal service delivery model and shortcomings in patient experiences in the NHS for patients with psoriatic arthritis (PsA). The objective of this work was to identify unmet needs perceived within the current health service delivery model for PsA from the UK Psoriatic Arthritis Priority Setting Partnership (PsA-PSP).

Methods

An online survey was conducted in 2020 and distributed to people with PsA, their carers and clinicians to identify research priorities in PsA. The participants were asked to submit three questions unanswered in PsA research. A proportion of submissions related to health service delivery were identified, which were deemed as out of scope for the main PsA-PSP but nevertheless important to report. Content analysis was used to analyse these submissions separately.

Results

We reviewed 138 submissions that were not related to the James Lind PSP and research priorities in PsA. Among these, 118 (85.5%) were focused on health service delivery and were classified into five main themes: rheumatology service, primary care navigation, education, holistic care, and ethnicity, diversity and inclusion. Further analysis within the rheumatology service theme revealed additional sub-themes that emphasized integrating multidisciplinary services, improving access to advice lines and ensuring fair access to treatments.

Conclusion

The five key themes provide valuable insights into the important areas of interest within health service delivery in the UK. By understanding these themes, policymakers, healthcare providers and researchers can better prioritize their efforts and address the specific care needs of people with PsA, their care providers and clinicians.

Weiterlesen

]]>132Wed, 09 Jul 2025 18:37:42 +0000Rutin ameliorates imiquimod-induced psoriasis-like skin lesions by inhibiting oxidative stress injury and the inflammatory response in mice via the Keap1/Nrf2 signaling pathway.https://www.psoriasis-news.de/articles.html/1_articles/rutin-ameliorates-imiquimod-induced-psoriasis-like-skin-lesions-by-inhibiting-oxidative-stress-injury-and-the-inflammatory-response-in-mice-via-the-keap1nrf2-signaling-pathway-r131/Weiterlesen

]]>131Wed, 09 Jul 2025 18:37:42 +0000Identification of miR-190a-5p and miR-26b-5p as Potential microRNA Biomarkers for Psoriatic Arthritis.https://www.psoriasis-news.de/articles.html/1_articles/identification-of-mir-190a-5p-and-mir-26b-5p-as-potential-microrna-biomarkers-for-psoriatic-arthritis-r130/ObjectivePsoriatic arthritis (PsA) is a chronic immune-mediated inflammatory arthritis that develops in 30% of patients with psoriasis, leading to increased morbidity and mortality and reduced quality of life. MicroRNAs (miRNAs) modulate gene expression and have been associated with the pathogenesis of immune-mediated disorders. We aimed to identify miRNAs that can be used as biomarkers for the development of PsA in patients with psoriasis.

Methods

miRNA expression levels were assessed in serum samples from 28 patients with PsA, 35 patients with cutaneous psoriasis without arthritis (PsC), and 28 healthy controls through next-generation sequencing. Differential expression was assessed by linear modeling with empirical Bayes moderation corrected for sequencing batch, age, sex, and duration of psoriasis. For validation, we measured the expression of >191 genes predicted to be targeted by the dysregulated miRNAs using a custom NanoString probe panel in an independent cohort of 144 patients with PsA and 88 patients with PsC. The enrichment of specific pathways corresponding to the differentially expressed gene targets was examined using pathDIP.

Results

In the discovery cohort, the miRNA miR-190a-5p was significantly down-regulated in patients with PsA compared to those with PsC (P< 0.05), and both miR-190a-5p and miR-26b-5p were down-regulated in patients with PsA versus healthy controls (P < 0.05). In the validation cohort, 26 gene targets of both of these miRNAs were differentially expressed. These genes were enriched in signaling pathways associated with bone formation and regeneration: Wnt and transforming growth factor β.

Conclusion

Serum expression levels of miR-190a-5p and miR-26b-5p can potentially serve as biomarkers for PsA development.

Weiterlesen

]]>130Wed, 09 Jul 2025 18:37:42 +0000TNF-alpha inhibitors reduce the incidence of psoriatic arthritis in patients with psoriasis: a propensity score-matched cohort study.https://www.psoriasis-news.de/articles.html/1_articles/tnf-alpha-inhibitors-reduce-the-incidence-of-psoriatic-arthritis-in-patients-with-psoriasis-a-propensity-score-matched-cohort-study-r129/ObjectivesConflicting data exist on TNF inhibitors' (TNFi) role in preventing psoriatic arthritis (PsA) in psoriasis. Using propensity score matching, we compared PsA incidence in severe psoriasis patients treated with TNFi versus narrow-band ultraviolet B (nbUVB) phototherapy over a decade of follow up.

Methods

Consecutive adults with severe psoriasis prescribed TNFi or nbUVB phototherapy between September 2005 and September 2010 were enrolled. Of 946 patients, 497 received TNFi (median follow-up 9.6±2.6 years) and 449 underwent nbUVB (9.4±5.9 years). All had rheumatologist assessment before therapy and for PsA diagnosis. PS matching adjusted for factors linked to PsA, including arthralgia, family history, BMI, PASI, and psoriasis distribution, including nails.

Results

After propensity score matching, the TNFi cohort contributed 2705.5 person-years of follow-up (mean 9.1 ± 2.9 years), and the nbUVB cohort 2654.1 person-years (mean 8.9 ± 5.4 years). The PsA incidence rate per 100 patients was 1.18 (0.84-1.52) in the TNFi group and 2.48 (2.24-2.72) in the nbUVB group, yielding an incidence rate ratio of 2.1 (1.37-2.98, p = 0.0002). A time-dependent Cox model confirmed that TNFi treatment was associated with a significantly lower risk of PsA (HR = 0.32, p < 0.0001). Arthralgia (HR = 7.68, p < 0.0001), nail psoriasis (HR = 1.93, p = 0.0004), and higher PASI score (HR = 1.03 per point, p = 0.0096) were independent predictors of PsA.

Conclusion

This PS-matched study shows a clear benefit of TNFi versus nbUVB in PsA reduction in severe psoriasis patients over nearly a decade of therapy.

Weiterlesen

]]>129Wed, 09 Jul 2025 18:37:42 +0000Global Recruiting Patterns Affect Placebo Response Rates In Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/global-recruiting-patterns-affect-placebo-response-rates-in-clinical-trials-of-psoriatic-arthritis-and-plaque-psoriasis-r128/BackgroundPlacebo effects are a significant challenge in the conduct of clinical trials. We explored how global recruitment patterns influence the extent of placebo responses in randomized controlled trials of psoriatic arthritis and plaque psoriasis.

Methods

We conducted an analysis of 51 trials (6,843 patients; 52±5.7% female) in psoriatic arthritis, and 43 trials (5,671 patients; 32±7.1% female) in plaque psoriasis investigating biological and targeted synthetic therapeutics. We investigated to what extent global recruitment patterns are related to the extent of response rates in the placebo arms of these clinical trials by investigating underlying socioeconomic factors using the average per capita gross national income (GNI; weighted for recruiting study centers per country) as proxy of these patterns in linear mixed models.

Findings

We identified a negative association of GNI and placebo response rates on the primary endpoints across psoriatic arthritis trials (ACR20: β=-5.7% per 10,000 international Dollars; 95% CI: -7.8% to -3.5%; p<0.001) and plaque psoriasis trials (PASI75%: β=-1.1%; 95% CI: -2.0 to -0.3; p=0.011). Sensitivity analyses using other outcome measures and alternative economic metrics, such as the UN Human Development Index and WHO out-of-pocket health expenditures were confirmatory.

Interpretation

The global expansion of trial recruitment to less affluent countries may increase placebo rates in studies of psoriatic arthritis and plaque psoriasis. These higher placebo rates may reflect the higher perceived benefit in these countries, leading to regression to the mean after patients have been successfully enrolled.

Weiterlesen

]]>128Wed, 09 Jul 2025 18:37:42 +0000Identification of mitophagy-related biomarkers with immune cell infiltration in psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/identification-of-mitophagy-related-biomarkers-with-immune-cell-infiltration-in-psoriasis-r127/BackgroundPsoriasis is an inflammatory disorder characterized by scaly erythematous plaques and significant comorbidities. Recent studies have suggested that impaired mitophagy, the cellular mechanism for removing dysfunctional mitochondria, may contribute to the pathogenesis of psoriasis.

Methods

In this study, we analyzed bulk RNA sequencing data from 167 healthy individuals and 177 patients with psoriasis obtained from the Gene Expression Omnibus database (GSE30999 and GSE54456). Mitophagy-related genes were isolated using weighted gene co-expression network analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed and protein-protein interaction networks were constructed for the functional enrichment of genes associated with mitophagy. The correlations between genes associated with mitophagy, signaling pathways, and immune cell infiltration were analyzed. The potential diagnostic value of genes associated with mitophagy was evaluated using receiver operating characteristic (ROC) curves, which were validated in imiquimod-induced psoriatic skin lesions in mice.

Results

We identified 3,839 differentially expressed genes between healthy individuals and patients with psoriasis, and 23 genes were selected as hub genes showing a high correlation with mitophagy in psoriasis. GO and KEGG analyses revealed that hub and associated genes were significantly correlated with skin functions, such as epidermal development and keratinocyte differentiation. In addition, mitophagy-related genes were negatively associated with pro-inflammatory and pro-proliferation pathways in psoriasis. Among the immune cells, CD4+ T cells were most significantly affected by mitophagy-related genes. ROC analysis demonstrated that mitophagy-related genes, especially ACER1, C1ORF68, CST6, FLG2, GJB3, GJB5, GPRIN2, KRT2, and SPRR4 were potential biomarkers of psoriasis for use in diagnosis or treatment.

Conclusions

Mitophagy-related genes play crucial roles in psoriasis and have potential use as biomarkers, providing insights into disease mechanisms and therapeutic targets. Further research may lead to the development of new strategies for psoriasis management.

Weiterlesen

]]>127Wed, 09 Jul 2025 18:37:42 +0000Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification.https://www.psoriasis-news.de/articles.html/1_articles/real-world-skin-clearance-and-quality-of-life-with-risankizumab-in-patients-with-psoriasis-with-moderate-skin-involvement-and-those-eligible-for-systemic-therapy-per-international-psoriasis-council-classification-r126/IntroductionThe International Psoriasis Council (IPC) reclassified patients eligible for systemic therapy to include those with body surface area (BSA) > 10%, psoriasis lesions in high-impact areas, or failure of topical therapy. Risankizumab is an interleukin-23 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis. This retrospective study evaluated the real-world effectiveness of risankizumab in patients with BSA 3-10% and patients meeting IPC systemic therapy criteria, addressing existing gaps in knowledge regarding its effectiveness in these patient groups.

Methods

Biologic-naïve adults with moderate-to-severe plaque psoriasis who initiated risankizumab between April 2019 and August 2023 and were treated for 12 (± 3) months were identified from the CorEvitas Psoriasis Registry and stratified by baseline BSA. At 12 months, skin clearance was assessed by achievement of Psoriasis Area Severity Index (PASI) 90, PASI 100, and National Psoriasis Foundation (NPF) treat-to-target goals. Patient-reported outcomes (PROs) included achievement of Dermatology Life Quality Index (DLQI) 0/1, improvements in psoriasis symptoms, and work and activity impairment.

Results

Of 272 patients analyzed, 123 had BSA 3-10% (78 had any high-impact area involvement and 105 had prior topical therapy experience) and 149 patients had BSA > 10%. Among those with BSA 3-10%, 77.9% achieved PASI 90 and 67.2% achieved PASI 100. NPF acceptable and target responses were met by 95.3% and 87.9%, respectively. Regarding PROs, 68.1% of patients with moderate skin involvement (BSA 3-10%) attained a DLQI score of 0/1. Significant improvements from baseline in psoriasis symptoms and reductions in work and life impairments were also reported (P < .001). Comparable positive outcomes were observed across all IPC systemic therapy eligible patient subgroups.

Conclusion

In patients with BSA 3-10% and those systemic-eligible per IPC classification, continuous treatment with risankizumab for 12 months resulted in high levels of skin clearance and improvements in PROs.

Weiterlesen

]]>126Wed, 09 Jul 2025 18:37:42 +0000Predicting abnormal epicardial adipose tissue in psoriasis patients by integrating radiomics from non-contrast chest CT with serological biomarkers.https://www.psoriasis-news.de/articles.html/1_articles/predicting-abnormal-epicardial-adipose-tissue-in-psoriasis-patients-by-integrating-radiomics-from-non-contrast-chest-ct-with-serological-biomarkers-r125/BackgroundPsoriasis patients frequently present with cardiovascular comorbidities, which maybe associated with abnormal epicardial adipose tissue (EAT). This study aimed to evaluate the predictive value of radiomics features derived from non-contrast chest CT (NCCT) combined with serological parameters for identifying abnormal EAT in psoriasis.

Methods

In this retrospective case-control study, we enrolled consecutive psoriasis patients who underwent chest NCCT between September 2021 and February 2024, along with a matched healthy control group. Psoriasis patients were stratified into mild-to-moderate (PASI ≤ 10) and severe (PASI > 10) groups based on the Psoriasis Area and Severity Index (PASI). Using TIMESlice, we extracted EAT volume, CT values, and 86 radiomics features. The cohort was randomly divided into a training (70%) and test (30%) set. LASSO regression selected radiomic features to calculate the Rad_Score. Serum uric acid (UA) and C-reactive protein (CRP) levels were collected. We compared EAT volume, CT values, Rad_Score, UA, and CRP between groups and developed three models: Model A (UA, CRP, EAT CT values), Model B (Rad_Score), and Model C (UA, CRP, EAT CT values, Rad_Score). Model accuracy was evaluated using ROC curves (P < 0.05).

Results

The study included 77 psoriasis patients and 76 matched controls. Psoriasis patients had higher UA and CRP levels than controls (both P < 0.001). EAT CT value was higher in psoriasis (P = 0.020), with no volume difference. Eight radiomics features and Rad_Score significantly differed between groups (P < 0.001), and Rad_Score also higher in severe group than that in mild-to-moderate group (P < 0.001). Model C showed the highest AUC in both sets: training 0.947 and test 0.895, indicating superior predictive performance.

Conclusions

Combining radiomics features, EAT CT values, UA, and CRP in a predictive model accurately predicts EAT abnormalities in psoriasis, potentially improving cardiovascular comorbidity diagnosis.

Clinical trial number

Not applicable.

Weiterlesen

]]>125Wed, 09 Jul 2025 18:37:42 +0000Exploring the relationship between novel measurements of abdominal obesity and psoriasis: a cross-sectional study from the NHANES database.https://www.psoriasis-news.de/articles.html/1_articles/exploring-the-relationship-between-novel-measurements-of-abdominal-obesity-and-psoriasis-a-cross-sectional-study-from-the-nhanes-database-r124/Weiterlesen

]]>124Wed, 09 Jul 2025 18:37:42 +0000Quality of life in mycosis fungoideshttps://www.psoriasis-news.de/articles.html/1_articles/quality-of-life-in-mycosis-fungoides-r123/No abstract supplied.

Weiterlesen

]]>123Thu, 26 Jun 2025 16:51:07 +0000Psoriasis Relapse: Exploring the Role of Epigenetics, Metabolic Reprogramming, and Inflammatory Memory.https://www.psoriasis-news.de/articles.html/1_articles/psoriasis-relapse-exploring-the-role-of-epigenetics-metabolic-reprogramming-and-inflammatory-memory-r121/Background: Psoriasis is a chronic autoimmune condition characterized by recurrent episodes of skin inflammation. Despite progress in treatment, managing flare-ups of psoriasis remains a significant hurdle once the therapy is halted. This review aims to unravel the enigma of relapse by examining the interactions between epigenetics, metabolic reprogramming, and inflammatory memory.Methods and Results: Skin-resident memory T cells and keratinocytes with a history of inflammation play crucial roles in the metabolic and epigenetic alterations observed during relapse. This review explores epigenetic factors involved in the recurrence of psoriasis, such as histone alterations, chromatin restructuring, and non-coding RNAs. Furthermore, we explored environmental influences, metabolic reprogramming, and genetic predispositions that influence the persistence and recurrence of psoriasis. We also outline the function of the gut-brain-skin axis in this scenario. Finally, we discuss pharmacological strategies for managing psoriasis relapse, including targeted biologics.Conclusion: This review provides a comprehensive summary on the intricate epigenetic, molecular, metabolic and environmental cues that exacerbate or facilitate psoriasis relapse. In summary, it also provides an enticing update on the therapeutics currently employed to treat psoriasis relapse.

Weiterlesen

]]>121Thu, 26 Jun 2025 16:19:29 +0000IL-17A in psoriatic arthritis: mechanistic insights, clinical implications, and advances in therapeutic strategies.https://www.psoriasis-news.de/articles.html/1_articles/il-17a-in-psoriatic-arthritis-mechanistic-insights-clinical-implications-and-advances-in-therapeutic-strategies-r120/IntroductionPsoriatic arthritis (PsA) is an immune-inflammatory disease involving skin and synovial-entheseal compartments. The understanding of IL-17 biological function has revolutionized the understanding of PsA pathogenesis and, consequently, its therapeutic approach.

Areas covered

In this review article, we have outlined the primary evidence regarding the biological functions of IL-17A in PsA, and summarized data from randomized controlled trials (RCTs) on PsA and psoriasis approved secukinumab, ixekizumab, bimekizumab, brodalumab, and emerging IL-17 inhibitors.

Expert opinion

The biologic disease-modifying antirheumatic drugs (bDMARDs), secukinumab, and ixekizumab target interleukin-17A (IL-17A), and bimekizumab, which simultaneously neutralizes IL-17A and IL-17F, have demonstrated efficacy in treating both peripheral and axial articular manifestations of PsA, as well in improving skin involvement, enthesitis and dactylitis. Brodalumab, which inhibits the IL-17 receptor A (IL-17RA), represent an efficacious strategy for psoriasis.Continued research into the role of IL-17s in PsA pathogenesis is crucial for improving our understanding of the disease and developing more effective therapeutic strategies. Further research and advancements in biologic therapies will refine IL-17 inhibitory strategies, potentially improving outcomes for PsA patients, and other immune-mediated diseases.

Weiterlesen

]]>120Thu, 26 Jun 2025 16:19:29 +0000Extracellular Vesicles from miR-146a Overexpressing Mesenchymal Stem Cells Attenuate ‎Imiquimod-Induced Psoriasis by Regulating Cytokine Expression.https://www.psoriasis-news.de/articles.html/1_articles/extracellular-vesicles-from-mir-146a-overexpressing-mesenchymal-stem-cells-attenuate-%E2%80%8Eimiquimod-induced-psoriasis-by-regulating-cytokine-expression-r119/BackgroundPsoriasis is a chronic inflammatory skin disorder characterized by elevated levels of proinflammatory cytokines. Mesenchymal stem cells (MSCs) have demonstrated therapeutic potential, yet the specific mechanisms involved are not fully understood.

Objective

To investigated the effectiveness of extracellular vesicles (EVs) derived from MSCs that were genetically modified to overexpress miR-146a, in a mouse model of psoriasis.

Methods

To enhance miR-146a expression, MSCs were transfected, and their EVs were subsequently purified. Thirty mice were randomly assigned to three groups and induced with imiquimod cream to develop psoriasis-like skin lesions. The treatment groups included: (1) a control group administered PBS, (2) a group treated with EVs containing a control miRNA (miR-control EVs), and (3) a group receiving EVs enriched with miR-146a (miR-146a-EVs). EVs were administered intravenously and lesions were evaluated. Following intravenous administration of EVs, the severity of skin lesions was assessed. Concentrations of key cytokines, including IFN-γ, IL-17, TNF-α, IL-23, IL-6, IL-1β, TGF-β, IL-10, and IL-4, were quantified in both spleen and skin tissue lysates using ELISA and qRT-PCR techniques.

Results

The experimental findings demonstrated that the administration of miR-146a-enriched EVs led to a significant improvement in clinical symptoms. There were substantial reductions observed in combined erythema, scaling, and skin thickness measurements compared to untreated controls. Additionally, levels of proinflammatory cytokines IFN-γ, IL-17, TNF-α, IL-23, IL-6, and IL-1β were significantly downregulated in the miR-146a-EV group, while anti-inflammatory TGF-β, IL-10 and IL-4 were upregulated. The same results were obtained in the spleens of mice.

Conclusion

EVs derived from miR-146a-modified MSCs effectively reduced psoriasis-like inflammation by modulating cytokine expression. This novel cell-free therapy holds promise for the treatment of psoriasis.

Weiterlesen

]]>119Thu, 26 Jun 2025 16:19:29 +0000Short-Chain Fatty Acids and Their Role in Modulating Autoimmune Responses in Psoriasis: Insights from Recent Microbiota Research.https://www.psoriasis-news.de/articles.html/1_articles/short-chain-fatty-acids-and-their-role-in-modulating-autoimmune-responses-in-psoriasis-insights-from-recent-microbiota-research-r118/Weiterlesen

]]>118Thu, 26 Jun 2025 16:19:29 +0000Investigating the efficacy of calcipotriol-acitretin combination therapy versus monotherapy protocols in psoriasis and its effect on serum inflammatory factors: a systematic review and meta-analysis.https://www.psoriasis-news.de/articles.html/1_articles/investigating-the-efficacy-of-calcipotriol-acitretin-combination-therapy-versus-monotherapy-protocols-in-psoriasis-and-its-effect-on-serum-inflammatory-factors-a-systematic-review-and-meta-analysis-r117/Background/objectivesThe mechanism of action of treatment drugs for psoriasis is based on anti-inflammation and the inhibition of epidermal proliferation, and retinoids and vitamin D3 derivatives are first-line therapy drugs for psoriasis. This meta-analysis aimed to comprehensively evaluate the efficacy and safety of calcipotriol-acitretin combination therapy for psoriasis and investigate its effect on serum inflammatory factors.

Methods

A systematic search of PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, Chinese biomedical literature service system (SinoMed), and Chinese Biomedical Journal Database (VIP), from the earliest record until Dec.13, 2024, was conducted. The outcomes were overall effective rate, Psoriasis Area and Severity Index (PASI) scores, inflammatory factor level and side effects.

Results

A total of 13 studies with 1196 patients were included in this meta-analysis. The results of this study show that the calcipotriol-acitretin combination therapy could improve the total effective rate when compared with acitretin [RR = 1.25, 95% CI (1.18, 1.33)] or calcipotriol [RR = 1.36, 95% CI (1.20, 1.56)] monotherapy. The combined therapy could decrease the PASI score observably when compared with acitretin monotherapy [SMD =  - 2.26, 95% CI (-3.24, -1.28)] or calcipotriol monotherapy [SMD =  - 3.79, 95% CI (-5.78, -1.79)]. Calcipotriol-acitretin combination therapy remarkably reduced the levels of TNF-α, IL-23, IL-17, INF-γ and IL-6 in serum, while increasing the levels of IL-4 and IL-10 within the serum, compared to acitretin monotherapy. This combination therapy did not increase the risk of skin irritation & burning pain, dry skin and perioral dermatitis. Notably, the incidence of perioral dermatitis was lower in combination therapy than acitretin monotherapy [P = 0.04, RR = 0.24, 95% CI (0.06, 0.93)].

Conclusions

The calcipotriol-acitretin combination therapy could be a safe and effective therapeutic strategy in the treatment of psoriasis. However, the lack of PROSPERO registration and the high heterogeneity in this study limited the conclusion, and more high-quality RCTs were needed for further evaluation.

Weiterlesen

]]>117Thu, 26 Jun 2025 16:19:29 +0000Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: another mosaic tile in the definition of a still undefined subset of patients.https://www.psoriasis-news.de/articles.html/1_articles/patients-with-psoriatic-arthritis-and-comorbid-metabolic-syndrome-show-a-difficult-to-treat-phenotype-another-mosaic-tile-in-the-definition-of-a-still-undefined-subset-of-patients-r116/ObjectivePsoriatic arthritis (PsA) is a chronic inflammatory condition associated with psoriasis and characterised by heterogeneous clinical manifestations, including peripheral and axial arthritis, enthesitis and dactylitis. A subset of patients exhibits a 'difficult-to-treat' (D2T) phenotype, necessitating complex therapeutic strategies. Metabolic syndrome (MetS) is highly prevalent in PsA patients and has been implicated in increased disease activity.This study aimed to evaluate the impact of MetS on the development of D2T phenotype in PsA and its potential implications for disease management.

Methods

A cross-sectional study was conducted on PsA patients recruited from the Rheumatology Clinic at Fondazione Policlinico Campus Bio-Medico of Rome. Patients fulfilling the Classification Criteria for Psoriatic Arthritis criteria were assessed for disease activity and the presence of MetS according to National Cholesterol Education Programme Adult Treatment Panel III criteria. D2T PsA was defined based on the Rheumatoid Arthritis European Alliance of Associations for Rheumatolog criteria revised for PsA by Perrotta et al. Statistical analyses, including logistic regression and path analysis, were performed to explore associations between MetS and D2T PsA.

Results

Among 182 PsA patients, 42.94% met MetS criteria. The D2T subset (n=66) demonstrated a significantly higher prevalence of MetS (81.82% vs 29.37%, p<0.0001). Logistic regression revealed a strong association between MetS and D2T PsA (OR 7.56, 95% CI 2.53 to 22.56, p<0.0001), and path analysis confirmed MetS as an independent predictor of D2T phenotype.

Conclusions

MetS is strongly associated with a D2T phenotype in PsA, suggesting that metabolic comorbidities contribute to disease severity and treatment resistance. Addressing metabolic dysfunction may be crucial in optimising therapeutic outcomes in PsA management.

Weiterlesen

]]>116Thu, 26 Jun 2025 16:19:29 +0000Association between glucose intolerance and psoriatic arthritis features.https://www.psoriasis-news.de/articles.html/1_articles/association-between-glucose-intolerance-and-psoriatic-arthritis-features-r115/No abstract supplied.

Weiterlesen

]]>115Thu, 26 Jun 2025 16:19:29 +0000Mechanistic insights into epigenetic contributions to psoriasis pathogenesis and their clinical implications.https://www.psoriasis-news.de/articles.html/1_articles/mechanistic-insights-into-epigenetic-contributions-to-psoriasis-pathogenesis-and-their-clinical-implications-r114/Weiterlesen

]]>114Thu, 26 Jun 2025 16:19:29 +0000Identification of novel biomarkers related to pathogenesis and treatment of psoriasis based on integrated analysis of weighted gene co-expression network analysis and LASSO.https://www.psoriasis-news.de/articles.html/1_articles/identification-of-novel-biomarkers-related-to-pathogenesis-and-treatment-of-psoriasis-based-on-integrated-analysis-of-weighted-gene-co-expression-network-analysis-and-lasso-r113/Weiterlesen

]]>113Thu, 26 Jun 2025 16:19:29 +0000Systemic Lupus Erythematosus and Psoriasis Overlap: A Case Serieshttps://www.psoriasis-news.de/articles.html/1_articles/systemic-lupus-erythematosus-and-psoriasis-overlap-a-case-series-r112/No abstract supplied.

Weiterlesen

]]>112Thu, 26 Jun 2025 16:19:29 +0000